Loading...
BVMF
BLAU3
Market cap467mUSD
Jul 09, Last price  
10.35BRL
1D
-0.38%
1Q
-8.73%
IPO
-73.70%
Name

Blau Farmaceutica SA

Chart & Performance

D1W1MN
BVMF:BLAU3 chart
P/E
8.11
P/S
1.40
EPS
1.28
Div Yield, %
8.18%
Shrs. gr., 5y
11.37%
Rev. gr., 5y
7.57%
Revenues
1.70b
-2.96%
271,385,000299,073,000383,451,000430,933,000617,658,000782,165,000977,500,0001,181,804,0001,366,407,0001,406,909,0001,372,633,0001,754,376,0001,702,382,000
Net income
295m
+35.80%
15,197,00016,877,00023,062,00032,333,000103,128,000123,253,000200,238,000254,330,000325,222,000363,368,000249,809,000217,206,000294,955,000
CFO
222m
-56.18%
-2,740,00014,221,00017,061,00045,679,000126,632,00082,532,000221,290,000223,500,000153,976,000171,903,000188,060,000507,203,000222,241,000
Dividend
Dec 19, 20250.5628 BRL/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Blau FarmacĂȘutica S.A. operates as a pharmaceutical enterprise, supplying private label medications across Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. Its extensive product portfolio encompasses a broad spectrum of therapeutic areas, including immunology, hematology, oncology, nephrology, specialized treatments, and antibiotics. The company's offerings also extend to biological drugs, oral and injectable therapies for cancer, specialized treatments for infectious diseases, and a range of prescription and over-the-counter products like dermo-medicines and contraceptives, catering to both retail and non-retail markets. Additionally, Blau provides pharmaceuticals derived from blood, biological and biotechnological agents, and antiretroviral drugs. Its client base includes hospitals, private medical clinics, chemotherapy and hemodialysis centers, and public health institutions. Established in 1987, the firm's corporate headquarters are situated in Cotia, Brazil.
IPO date
Apr 19, 2021
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT